[go: up one dir, main page]

WO2007039458A3 - Hiv peptide conjugates and uses thereof - Google Patents

Hiv peptide conjugates and uses thereof Download PDF

Info

Publication number
WO2007039458A3
WO2007039458A3 PCT/EP2006/066526 EP2006066526W WO2007039458A3 WO 2007039458 A3 WO2007039458 A3 WO 2007039458A3 EP 2006066526 W EP2006066526 W EP 2006066526W WO 2007039458 A3 WO2007039458 A3 WO 2007039458A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigen
compositions
peptide conjugates
hiv peptide
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/066526
Other languages
French (fr)
Other versions
WO2007039458A2 (en
Inventor
Martin Bachmann
Philippe Saudan
Andrea Jegerlehner
Till Alexander Roehn
Gary Jennings
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytos Biotechnology AG
Original Assignee
Cytos Biotechnology AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytos Biotechnology AG filed Critical Cytos Biotechnology AG
Publication of WO2007039458A2 publication Critical patent/WO2007039458A2/en
Publication of WO2007039458A3 publication Critical patent/WO2007039458A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18123—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The invention provides composition comprising a virus-like particle (VLP) linked to at least one antigen, wherein said antigen is HIV gpl60 peptide. The invention also provides a process for producing the composition. The compositions of this invention are useful in the production of vaccines, in particular, for the prevention and treatment of diseases. Moreover, the compositions of the invention induce efficient immune responses, in particular antibody responses.
PCT/EP2006/066526 2005-09-21 2006-09-20 Hiv peptide conjugates and uses thereof Ceased WO2007039458A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05108697.3 2005-09-21
EP05108697 2005-09-21

Publications (2)

Publication Number Publication Date
WO2007039458A2 WO2007039458A2 (en) 2007-04-12
WO2007039458A3 true WO2007039458A3 (en) 2007-06-07

Family

ID=37499997

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/066526 Ceased WO2007039458A2 (en) 2005-09-21 2006-09-20 Hiv peptide conjugates and uses thereof

Country Status (1)

Country Link
WO (1) WO2007039458A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009011912A1 (en) * 2007-07-18 2009-01-22 Bristol-Myers Squibb Company A composition for treating hiv comprising virus-like particles
EP3520809B1 (en) * 2012-02-03 2025-08-06 Emory University Immunostimulatory compositions.
US20190046638A1 (en) * 2016-04-01 2019-02-14 Checkmate Pharmaceuticals, Inc. Fc RECEPTOR-MEDIATED DRUG DELIVERY
WO2019160866A2 (en) 2018-02-13 2019-08-22 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
JP7511478B2 (en) 2018-04-09 2024-07-05 チェックメイト ファーマシューティカルズ Packaging of oligonucleotides into virus-like particles

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987007616A1 (en) * 1986-06-12 1987-12-17 Biogen N.V. Peptides involved in the pathogenesis of hiv infection
EP0330359A2 (en) * 1988-02-25 1989-08-30 Bio-Rad Laboratories, Inc. Composition useful in the diagnosis and treating of HIV-1 infection
WO1992022572A1 (en) * 1991-06-13 1992-12-23 Replico Medical Ab New hiv-1 gag and env peptides, diagnostic
WO2004084940A1 (en) * 2003-03-26 2004-10-07 Cytos Biotechnology Ag Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use
EP1466924A1 (en) * 2003-04-11 2004-10-13 Institut Pasteur Synthetic peptide vaccines for HIV: the CBD epitope as an effective immunogen to elicit broadly neutralizing antibodies against HIV
WO2006027468A2 (en) * 2004-08-27 2006-03-16 Commissariat A L'energie Atomique Hla-dp4 restricted t cd4+ du vih epitopes and the use thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987007616A1 (en) * 1986-06-12 1987-12-17 Biogen N.V. Peptides involved in the pathogenesis of hiv infection
EP0330359A2 (en) * 1988-02-25 1989-08-30 Bio-Rad Laboratories, Inc. Composition useful in the diagnosis and treating of HIV-1 infection
WO1992022572A1 (en) * 1991-06-13 1992-12-23 Replico Medical Ab New hiv-1 gag and env peptides, diagnostic
WO2004084940A1 (en) * 2003-03-26 2004-10-07 Cytos Biotechnology Ag Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use
EP1466924A1 (en) * 2003-04-11 2004-10-13 Institut Pasteur Synthetic peptide vaccines for HIV: the CBD epitope as an effective immunogen to elicit broadly neutralizing antibodies against HIV
WO2006027468A2 (en) * 2004-08-27 2006-03-16 Commissariat A L'energie Atomique Hla-dp4 restricted t cd4+ du vih epitopes and the use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HAFFAR O K ET AL: "HIV-SPECIFIC HUMORAL AND CELLULAR IMMUNITY IN RABBITS VACCINATED WITH RECOMBINANT HUMAN IMMUNODEFICIENCY VIRUS-LIKE GAG-ENV PARTICLES", VIROLOGY, vol. 183, no. 2, 1991, pages 487 - 495, XP002412044, ISSN: 0042-6822 *
LUO L ET AL: "Induction of V3-specific cytotoxic T lymphocytes responses by HIV gag particles carrying multiple immunodominant V3 epitopes of gp120", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 240, no. 2, 20 January 1998 (1998-01-20), pages 316 - 325, XP002291384, ISSN: 0042-6822 *
TOBIN G J ET AL: "Chimeric HIV-1 Virus-like Particles Containing gp120 Epitopes as a Result of a Ribosomal Frameshift Elicit Gag- and SU-Specific Murine Cytotoxic T-Lymphocyte Activities", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 236, no. 2, 29 September 1997 (1997-09-29), pages 307 - 315, XP004452082, ISSN: 0042-6822 *

Also Published As

Publication number Publication date
WO2007039458A2 (en) 2007-04-12

Similar Documents

Publication Publication Date Title
WO2009080823A3 (en) Nerve growth factor conjugates and uses thereof
WO2006045796A3 (en) Gastric inhibitory polypeptide (gip) antigen arrays and uses thereof
WO2006097530A3 (en) Cat allergen fusion proteins and uses thereof
WO2004007538A3 (en) Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
MX2007003171A (en) Virus-like particles comprising a fusion protein of the coat protein of ap205 and an antigenic polypeptide.
WO2002056905A3 (en) Molecular antigen array
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
WO2006037787A3 (en) Vlp-antigen conjugates and their uses as vaccines
WO2006063974A3 (en) Il-15 antigen arrays and uses thereof
WO2010010466A3 (en) Neutralizing anti-influenza a virus antibodies and uses thereof
WO2004009124A3 (en) Ghrelin-carrier conjugates
ATE489969T1 (en) PACKAGED VIRUS-LIKE PARTICLES IN COMBINATION WITH CPG FOR USE AS ADJUVANTS WITH ALLERGENS. MANUFACTURING PROCESS AND USE
WO2009018500A8 (en) Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
WO2003040164A3 (en) Antigen arrays presenting il-5, il-3 or eotaxin for treatment of allergic eosinophilic diseases
WO2003039225A3 (en) Antigen arrays comprising rankl for treatment of bone disease
WO2005068639A3 (en) Particle-induced ghrelin immune response
WO2005120558A3 (en) Methods for making compositions comprising heat shock proteins or alpha-2-macroglobulin for the treatment of cancer and infectious disease
WO2005117983A3 (en) Carrier conjugates of tnf-peptides
WO2006027300A3 (en) Carrier conjugates of gnrh-peptides
WO2007039458A3 (en) Hiv peptide conjugates and uses thereof
WO2003059386A3 (en) Prion protein carrier-conjugates
WO2011057160A3 (en) Method to improve the immunogenicity of vaccine antigens by modification of cleavage sites in hiv-1 gp 120
WO2002034288A3 (en) Vaccine for treating allergy
MX2007003954A (en) Vlp-antigen conjugates and their uses as vaccines.
WO2007008093A3 (en) A method of manufacturing a recombinant vaccine against viral rabbit haemorrhagic disease, the vaccine, the application of a recombinant antigen in the manufacture of the vaccine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06806784

Country of ref document: EP

Kind code of ref document: A2